18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?

Several studies have documented that 18F-FDG PET is more accurate than CT for assessment of tumor response to chemotherapy in patients with Hodgkin’s lymphoma (HL) and high-grade (aggressive) non-Hodgkin’s lymphoma (NHL) (1,2). On the basis of these data, the International Workshop Criteria for assessment of tumor response in NHL have recently been revised to include 18F-FDG PET (3). A complete response (CR) is now based primarily on the findings on 18F-FDG PET. Patients with a residual mass of any size on CT are considered to be in CR as long as the mass is negative on 18F-FDG PET. Visual assessment has been found to be sufficient to assess tumor response on

[1]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Lammertsma,et al.  18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[5]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[6]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[7]  Adriaan A. Lammertsma,et al.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  J. Leonard,et al.  FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease , 2006, Cancer.

[9]  R. Wahl,et al.  Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[11]  A. Kirby,et al.  The role of FDG PET in the management of lymphoma: what is the evidence base? , 2007, Nuclear medicine communications.

[12]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[13]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[14]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Rowe,et al.  Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.

[17]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[18]  W. Wilson,et al.  FDG-PET lymphoma demonstration project invitational workshop. , 2007, Academic radiology.

[19]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.